The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. (“Sage” or “the Company”) (NASDAQ: SAGE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between April 12, 2021 and July 23, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before October 28, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Sage’s Zuranolone proved to be less effective in the treatment of major depressive disorder (“MDD”) than the Company had touted to investors. The FDA was unlikely to approve an NDA for Zuranolone. The Company’s SAGE-718 was less effective in treating mild cognitive impairment (“MCI”) than the company led shareholders to believe. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Sage, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240829534595/en/